This study reveals the MIAT-mediated mechanism of immune evasion in HCC, suggesting that the MIAT/miR-411-5p/STAT3/PD-L1 axis could serve as a novel therapeutic target for HCC treatment. Here, STAT3 is linked to hepatocellular carcinoma.